Xiang Ling, Wenjie Wu, Li Yan, Leslie Curtin, Melanie M. Farrauto, Sandra Sexton, Anmbreen Jamroze, Changjun Yu, Christos Fountzilas, Dean G. Tang, Fengzhi Li. Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.101001
Citation:
|
Xiang Ling, Wenjie Wu, Li Yan, Leslie Curtin, Melanie M. Farrauto, Sandra Sexton, Anmbreen Jamroze, Changjun Yu, Christos Fountzilas, Dean G. Tang, Fengzhi Li. Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.101001
|
Xiang Ling, Wenjie Wu, Li Yan, Leslie Curtin, Melanie M. Farrauto, Sandra Sexton, Anmbreen Jamroze, Changjun Yu, Christos Fountzilas, Dean G. Tang, Fengzhi Li. Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.101001
Citation:
|
Xiang Ling, Wenjie Wu, Li Yan, Leslie Curtin, Melanie M. Farrauto, Sandra Sexton, Anmbreen Jamroze, Changjun Yu, Christos Fountzilas, Dean G. Tang, Fengzhi Li. Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.101001
|
Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer
-
Xiang Linga,b
,
-
Wenjie Wua,b
,
-
Li Yanc
,
-
Leslie Curtind
,
-
Melanie M. Farrautod
,
-
Sandra Sextond
,
-
Anmbreen Jamrozea
,
-
Changjun Yue
,
-
Christos Fountzilasf,g,h
,
-
Dean G. Tanga,g,i
,
-
Fengzhi Lia,g,h,i
,
,
-
a Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14263, USA;
-
b Canget BioTekpharma LLC, Buffalo, New York 14203, USA;
-
c Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center Buffalo, New York 14263, USA;
-
d Comparative Oncology Shared Resources, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14263, USA;
-
e California Institute of Technology, Pasadena, California 91125, USA;
-
f Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14263, USA;
-
g Developmental Therapeutics (DT) Program, Roswell Park Comprehensive Cancer Center; Buffalo, New York 14263, USA;
-
h Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center; Buffalo, New York 14263, USA;
-
i Genitourinary (GU) Oncology Research Center, Roswell Park Comprehensive Cancer Center; Buffalo, New York 14263, USA
- Received Date:
Jan. 27, 2024
- Accepted Date:
May 09, 2024
- Rev Recd Date:
Apr. 25, 2024
- Available Online:
May 14, 2024